The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MedAssets's revenues will grow 7.4% and EPS will decrease 0.0%.
The average estimate for revenue is $154.2 million. On the bottom line, the average EPS estimate is $0.26.
Last quarter, MedAssets logged revenue of $163.0 million. GAAP reported sales were 11% higher than the prior-year quarter's $147.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.28. GAAP EPS were $0.04 for Q2 versus -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 78.7%, 60 basis points worse than the prior-year quarter. Operating margin was 12.3%, 160 basis points worse than the prior-year quarter. Net margin was 1.4%, 310 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $627.5 million. The average EPS estimate is $1.11.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 62 members out of 75 rating the stock outperform, and 13 members rating it underperform. Among 24 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give MedAssets a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MedAssets is outperform, with an average price target of $16.37.
- Add MedAssets to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why MedAssets, Inc. Jumped 30% Today
The healthcare performance improvement company is getting acquired.
Why MedAssets, Inc.'s Shares Crashed Today
Is this meaningful? Or just another movement?
3 Value Stocks Near 52-Week Lows Worth Buying
These three value stocks may have been beaten down in recent months, but they may not stay near their 52-week lows for much longer.